Compare GSK plc (GSK) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

KOLD, an inverse leveraged ETF tracking natural gas futures, trades at $28.53 with a 4.12% daily gain. Technical indicators show a bullish trend with strong moving average signals, though RSI levels suggest potential overbought conditions near $28-29 resistance. The fund's performance remains directly tied to natural gas price volatility, with recent news highlighting weather-driven demand fluctuations and geopolitical factors influencing the underlying commodity market.

As an inverse leveraged ETF, KOLD provides tactical exposure to declining natural gas prices but carries significant risks from daily rebalancing and contango in futures markets. Current bullish technical signals conflict with elevated RSI readings, suggesting near-term consolidation may precede the next directional move based on weather patterns and storage data.